ADEMPAS TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

RIOCIGUAT

Saadav alates:

BAYER INC

ATC kood:

C02KX05

INN (Rahvusvaheline Nimetus):

RIOCIGUAT

Annus:

1.5MG

Ravimvorm:

TABLET

Koostis:

RIOCIGUAT 1.5MG

Manustamisviis:

ORAL

Ühikuid pakis:

42

Retsepti tüüp:

Prescription

Terapeutiline ala:

VASODILATING AGENTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0154770003; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2013-09-19

Toote omadused

_ _
_ _
_ADEMPAS (Riociguat Tablets) _
_Page 1 of 46_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ADEMPAS®
riociguat (film-coated) tablet
Tablet, 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg for oral use
Professed standard
Soluble Guanylate Cyclase (sGC) Stimulator
Bayer Inc.
2920 Matheson Boulevard East
Mississauga, Ontario
L4W 5R6
http://www.bayer.ca
Date of Initial Authorization:
September 19, 2013
Date of Revision:
October 13, 2022
Submission Control Number: 262975
© 2022, Bayer Inc.
® TM see www.bayer.ca/tm-mc
All other trademarks are the property of their respective owners.
_ _
_ _
_ _
_ADEMPAS (Riociguat Tablets) _
_Page 2 of 46_
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
10/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................
4
1
INDICATIONS......................................................................................................................
4
1.1 Pediatrics
........................................................................................................................
4
1.2
Geriatrics.........................................................................................................................
4
2 CONTRAINDICATIONS
.........................................................................................................
4
4 DOSAGE AND
ADMINISTRATION...........................................................................................
5
4.1 Dosing Considerations
.......................................................................................................
5
4.2 Recommended Dose and Dosage Adjustment
.......................